Tag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Yu, Xinfeng ^a,b   Rao, Juan ^b   Lin, Jia ^b   Zhang, Zhi ^c   Cao, Lei ^b   Zhang, Xuemei ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HEBEI UNITED UNIVERSITY   (China)

^c TANGSHAN GONGREN HOSPITAL   (China)

Author keywords

CR1; Lung cancer; Polymorphism; Tag SNPs

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR;

ADULT; AGE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, COMPLEMENT;

EID: 84899575082     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-56     Document Type: Article

References (45)

1. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004, 25:158-164. 10.1016/j.it.2004.01.008, 15036044.
2. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res 2010, 8:1453-1465. 10.1158/1541-7786.MCR-10-0225, 20870736.
3. Liu D, Niu ZX. The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacol Immunotoxicol 2009, 31:524-535. 10.3109/08923970902845768, 19874218.
4. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989, 46:183-219.
5. Tas SW, Klickstein LB, Barbashov SF, Nicholson-Weller A. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol 1999, 163:5056-5063.
6. Wagner C, Ochmann C, Schoels M, Giese T, Stegmaier S, Richter R, Hug F, Hansch GM. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol Immunol 2006, 43:643-651. 10.1016/j.molimm.2005.04.006, 16360013.
7. Jozsi M, Prechl J, Bajtay Z, Erdei A. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J Immunol 2002, 168:2782-2788.
8. Rochowiak A, Niemir ZI. The structure and role of CR1 complement receptor in physiology. Pol Merkur Lekarski 2010, 28:79-83.
9. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol 1982, 129:2051-2060.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
11. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999, 36:929-939. 10.1016/S0161-5890(99)00115-7, 10698347.
12. Weis JH, Morton CC, Bruns GA, Weis JJ, Klickstein LB, Wong WW, Fearon DT. A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol 1987, 138:312-315.
13. Wilson JG, Wong WW, Murphy EE, Schur PH, Fearon DT. Deficiency of the C3b/C4b receptor (CR1) of erythrocytes in systemic lupus erythematosus: analysis of the stability of the defect and of a restriction fragment length polymorphism of the CR1 gene. J Immunol 1987, 138:2708-2710.
14. Xiang L, Rundles JR, Hamilton DR, Wilson JG. Quantitative alleles of CR1: coding sequence analysis and comparison of haplotypes in two ethnic groups. J Immunol 1999, 163:4939-4945.
15. Birmingham DJ, Chen W, Liang G, Schmitt HC, Gavit K, Nagaraja HN. A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b. Immunology 2003, 108:531-538. 10.1046/j.1365-2567.2003.01579.x, 1782929, 12667215.
16. Holers VM, Chaplin DD, Leykam JF, Gruner BA, Kumar V, Atkinson JP. Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc Natl Acad Sci U S A 1987, 84:2459-2463. 10.1073/pnas.84.8.2459, 304671, 3031685.
17. Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D, Tan L. Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease. Brain Res 2010, 1348:216-221.
18. He JR, Xi J, Ren ZF, Qin H, Zhang Y, Zeng YX, Mo HY, Jia WH. Complement receptor 1 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma. Asian Pac J Cancer Prev 2012, 13:6527-6531. 10.7314/APJCP.2012.13.12.6527, 23464487.
19. Srivastava A, Mittal B. Complement receptor 1 (A3650G RsaI and intron 27 HindIII) polymorphisms and risk of gallbladder cancer in north Indian population. Scand J Immunol 2009, 70:614-620. 10.1111/j.1365-3083.2009.02329.x, 19906204.
20. Ferreira CG. Lung cancer in developing countries. Am Soc Clin Oncol Educ Book 2013, 327-331. PMID:23714537.
21. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008, 40:616-622. 10.1038/ng.109, 2713680, 18385676.
22. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637. 10.1038/nature06885, 18385738.
23. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen WV, Spitz MR, Eisen T, Amos CI, Houlston RS. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008, 40:1407-1409. 10.1038/ng.273, 2695928, 18978787.
24. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, McLaughlin J, Shepherd F, Montpetit A, Narod S, Krokan HE, Skorpen F, Elvestad MB, Vatten L, Njølstad I, Axelsson T, Chen C, Goodman G, Barnett M, Loomis MM, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008, 40:1404-1406. 10.1038/ng.254, 2748187, 18978790.
25. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007, 171:715-727. 10.2353/ajpath.2007.070166, 1959484, 17640961.
26. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007, 25:1265-1275. 10.1038/nbt1342, 2966895, 17989689.
27. Hugli TE. Biochemistry and biology of anaphylatoxins. Complement 1986, 3:111-127.
28. Ostrand-Rosenberg S. Cancer and complement. Nat Biotechnol 2008, 26:1348-1349. 10.1038/nbt1208-1348, 2800820, 19060872.
29. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol 2008, 9:1225-1235. 10.1038/ni.1655, 2678913, 18820683.
30. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009, 30:286-292. 10.1016/j.it.2009.04.002, 2704572, 19428302.
31. Fan Q, He JF, Wang QR, Cai HB, Sun XG, Zhou XX, Qin HD, Shugart YY, Jia WH. Functional polymorphism in the 5′-UTR of CR2 is associated with susceptibility to nasopharyngeal carcinoma. Oncol Rep 2013, 30:11-16. 3729234, 23612877.
32. Cerhan JR, Novak AJ, Fredericksen ZS, Wang AH, Liebow M, Call TG, Dogan A, Witzig TE, Ansell SM, Habermann TM, Kay NE, Slager SL. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009, 145:614-623. 10.1111/j.1365-2141.2009.07675.x, 2820509, 19344414.
33. Zhang Z, Yu D, Yuan J, Guo Y, Wang H, Zhang X. Cigarette smoking strongly modifies the association of complement factor H variant and the risk of lung cancer. Cancer Epidemiol 2012, 36:e111-e115. 10.1016/j.canep.2011.11.004, 22197220.
34. Shen M, Vermeulen R, Rajaraman P, Menashe I, He X, Chapman RS, Yeager M, Thomas G, Burdett L, Hutchinson A, Yuenger J, Chanock S, Lan Q. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. Environ Mol Mutagen 2009, 50:285-290. 10.1002/em.20452, 2666781, 19170196.
35. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 1980, 152:20-30. 10.1084/jem.152.1.20, 2185895, 6967510.
36. Besaratinia A, Pfeifer GP. Second-hand smoke and human lung cancer. Lancet Oncol 2008, 9:657-666. 10.1016/S1470-2045(08)70172-4, 2740739, 18598930.
37. Coyle YM, Minahjuddin AT, Hynan LS, Minna JD. An ecological study of the association of metal air pollutants with lung cancer incidence in Texas. J Thorac Oncol 2006, 1:654-661. 10.1097/01243894-200609000-00009, 17409932.
38. Garshick E, Laden F, Hart JE, Rosner B, Smith TJ, Dockery DW, Speizer FE. Lung cancer in railroad workers exposed to diesel exhaust. Environ Health Perspect 2004, 112:1539-1543. 10.1289/ehp.7195, 1247618, 15531439.
39. Brennan P, Buffler PA, Reynolds P, Wu AH, Wichmann HE, Agudo A, Pershagen G, Jockel KH, Benhamou S, Greenberg RS, Merletti F, Winck C, Fontham ET, Kreuzer M, Darby SC, Forastiere F, Simonato L, Boffetta P. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer 2004, 109:125-131. 10.1002/ijc.11682, 14735478.
40. Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 2009, 15:303-307. 10.1097/MCP.0b013e32832c975a, 19417670.
41. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 2008, 8:605-615. 10.1586/14737140.8.4.605, 18402527.
42. Kullo IJ, Ding K, Shameer K, McCarty CA, Jarvik GP, Denny JC, Ritchie MD, Ye Z, Crosslin DR, Chisholm RL, Manolio TA, Chute CG. Complement receptor 1 gene variants are associated with erythrocyte sedimentation rate. Am J Hum Genet 2011, 89:131-138. 10.1016/j.ajhg.2011.05.019, 3135803, 21700265.
43. Teeranaipong P, Ohashi J, Patarapotikul J, Kimura R, Nuchnoi P, Hananantachai H, Naka I, Putaporntip C, Jongwutiwes S, Tokunaga K. A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. J Infect Dis 2008, 198:1880-1891. 10.1086/593338, 18954261.
44. Chen GB, Xu Y, Xu HM, Li MD, Zhu J, Lou XY. Practical and theoretical considerations in study design for detecting gene-gene interactions using MDR and GMDR approaches. PLoS One 2011, 6:e16981. 10.1371/journal.pone.0016981, 3046176, 21386969.
45. Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, Li MD. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 2007, 80:1125-1137. 10.1086/518312, 1867100, 17503330.